Drug intelligence / Profile preview

losartan + QingReMoShen

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

This appears to be a combination of losartan, an angiotensin II receptor blocker (ARB) used to treat hypertension, with QingReMoShen, which seems to be a traditional medicine or herbal supplement. Losartan works by blocking a substance in the body that causes blood vessels to tighten, thereby relaxing blood vessels and lowering blood pressure. Information about QingReMoShen and its specific interaction with losartan is not available in the provided data.

Targets

AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on losartan + QingReMoShen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on losartan + QingReMoShen.

Explore the full profile